Table 3. Significant bleeding events according to antithrombotic management.

ATD management	Bleeding case		Total	% Bleed/group	P value
	Yes	No
Antithrombotic group	4	110	114	(3.4 %,4/114)	0.601
1. Continue	2	61	63	(3.2 %,2/63)
ASA,cilostazol,other antiplatelet	2	61	63
2. Discontinue	1	40	41	(2.43 %,1/41)
Switched to ASA 1	0	14	14
Continued ASA 1	1	10	11
Other	0	16	16
3. Heparin replacement	1	9	10	(10 %,1/10)
Non-Antithrombotic group	2	792	794	(0.2 %,2/794)
Total	6	902	908	(0.7 %,6/908)

ASA, aspirin;

¹withdrew thienopyridine